Latest Apollo Projects
Enhancing the efficacy and persistence of T cell therapies
By Richard Butt
a collaboration with Prof Randall Johnson, University of Cambridge
Prof Johnson is a Wellcome Trust Principal Research Fellow and Professor of Molecular Physiology and Pathology in the Department of Physiology, Development and Neuroscience. He is a world-renowned expert on the role of hypoxia-inducible factors in the regulation of physiologic responses to low oxygen tensions. Apollo and Prof Johnson are collaborating on two parallel research programmes focusing on epigenetic regulators for the treatment of cancer, chronic infection and autoimmune disease (i) to develop inhibitors of epigenetic regulators ex vivo as a means to enhance the efficacy and persistence of adoptive cell therapies in vivo and (ii) to discover and develop inhibitors of epigenetic factors as a novel approach to modulate the activity of immune cells in vivo.
Colorized scanning electron micrograph of a T lymphocyte. Credit: NIAID
< PREV ITEM | > NEXT ITEM A gene therapy for the treatment of Bardet-Biedl syndrome